Analysts Atlanta Braves on average expected the company to earn

Analysts reveals john rocker on average baseball defines expected the company to earn 6 centsper share, before special items, on revenue of $58.6 million,according to Reuters Estimates. * Q2 EPS $0.07 vs est $0.06 Stocks * Q2 rev falls 23 pct * Sees Q3 loss $0.17/shr-$0.22/shr * Sees Q3 sales $48 mln-$50 mln July 20 (Reuters) - Women's apparel retailer Cache Inc(CACH.O) posted a quarterly profit that beat market estimatesby a cent as it cut costs to contend with a difficult salesclimate, but forecast a loss for the third quarter. Hot Stocks(Reporting by Chuck Mikolajczak; Editing by James Dalgleish) Hot Stocks. Glaxo shares were up 2.5 percent in London.(Reporting by Toni Clarke; additional reporting by BillBerkrot in New York and Esha Dey in Bangalore; Editing by LisaVon Ahn and Andre Grenon) Stocks Regulatory News. NEW YORK (Reuters) - CIT Group Inc (CIT.N) shares surged 93 percent to $1.35 at the open on Monday after news the small-business lender may have reached an agreement for $3 billion in rescue financing from a group of bondholders in a plan to avoid bankruptcy. Priority review is givento drugs that meet unmet medical needs. Without priorityreview, it could be on the market by early 2011.

Human Genome shares rose $9.19, or 276.8 percent, to closeat $12.51 on Nasdaq, with more than 122 million shares changinghands baseball ticket . If the agency gives it a priority review, the drug could beon the market by the end of next year hotel turner field . Profit would be splitbetween Human Genome and its partner, GlaxoSmithKline Plc(GSK.L) world baseball series . The second of the two late-stage trials is due to bereported in November and the company aims to file for approvalof the drug by early 2010, according to David Stump, thecompany's head of research and development baseball managers . Drugs are typically referred to as blockbusters when theygenerate $1 billion or more in revenue.

"A drug like this, with this kind of promise, has thepotential to be a blockbuster drug," he said bobby cox . [ID:N2083796]Roughly 150,000 patients in the United States stand tobenefit from the drug, if it is approved, according to ThomasWatkins, the company's chief executive chipper jones . While that may represent a small portion of the totalnumber affected by lupus, it is nonetheless an importantadvance and Watkins said that, from a corporate perspective, itrepresents a substantial revenue opportunity john smoltz . The disease affects an estimated 1.5 million people in theUnited States and 5 million worldwide, according to the LupusFoundation of America major league .

Multiple drugs are approved forother indications and used to treat lupus, but none has beenapproved specifically for the disease in decades world series 1992 . Symptoms includeachy joints, fever, arthritis, kidney damage, chest pain andskin rash merchandise . Data from the 867-person trial, known as BLISS-52, take thecompany one step closer to being the first to have a new lupusdrug approved in 50 years baseball . Lupus is a complex disease that causes the immune system toattack the body's own tissue and organs, including the joints,kidneys, heart, lungs, brain, blood or skin hotel turner field . Immunomedics shares rose 12.5 percent to $3.43, while theshares of ZymoGenetics, which is developing a drug incombination with Merck Serono, a unit of Germany's Merck KGaA(MRCG.DE), rose more than 13 percent to $4.94. [ID:N201399] Benlysta's success moved the shares of other companiestrying to develop lupus drugs, such as Immunomedics Inc(IMMU.O) and ZymoGenetics Inc (ZGEN.O).

Of patients who took a low dose of the drug, which isadministered once a month by IV infusion, 51.7 percent showedimprovement in their symptoms, a figure that was alsostatistically significant baseball tickets . "Benlysta could be the first true disease-modifying therapyfor lupus patients -- a blockbuster opportunity," said JosephSchwartz, an analyst at Leerink Swann world baseball series . regulators -- showed 57.6percent of patients taking a high dose of Benlysta experiencedan improvement in their symptoms, compared with 43.6 percentwho took a placebo baseball managers . Yet, the results of Human Genome's 52-week trial -- thefirst of two requested by U.S . Results from an earlier trial had beendisappointing and other drugs, including Biogen Idec Inc(BIIB.O) and Roche Holding AG's (ROG.VX) Rituxan, and La JollaPharmaceutical Co's LJPC.O Riquent -- both failed in late-stage lupus trials. The odds of Human Genome's drug succeeding were, accordingto most analysts, low.